Two Princeton University studies are opening important new windows into understanding an untreatable group of common genetic disorders known as RASopathies that are characterized by distinct facial features, developmental delays, cognitive impairment and heart problems. The findings could help point the way toward personalized precision therapies for these conditions. Although not widely known, RASopathies are among the most common genetic disorders, affecting approximately one child out of 1,000. RASopathies are caused by mutations within the RAS pathway, a biochemical system cells use to transmit information from their exterior to their interior. https://askpinkiepiesolutions.tumblr.com/ "Human development is very complex and it's amazing that it goes right so often. However, there are certain cases where it does not, as with RASopathies," said Granton Jindal, co-lead author of the two studies. Both Jindal and the other co-lead author, Yogesh Goyal, are graduate students in the Department of Chemical and Biological Engineering and the Lewis-Sigler Institute for Integrative Genomics (LSI). Jindal and Goyal do their thesis research in the lab of Stanislav Shvartsman, professor of chemical and biological engineering and LSI. "Our new studies are helping to explain the mechanisms underlying these disorders," Jindal said. These studies were published this year, one in the Proceedings of the National Academy of Sciences (PNAS) and the other in Nature Genetics online. The researchers made the discoveries in zebrafish and fruit flies -- animals commonly used as simplified models of human genetics and Jindal and Goyal's specialties, respectively. Due to the evolutionary similarities in the RAS pathway across diverse species, changes in this pathway would also be similar. Thus, it is likely that significant parts of findings in animals would apply to humans as well, although further research is needed to confirm this. The first paper published Jan. 3 in PNAS presented a way to rank the severity of different mutations involved in RASopathies. The researchers introduced 16 mutations one at a time in developing zebrafish embryos. As each organism developed, clear differences in the embryos' shapes became evident, revealing the strength of each mutation. The same mutant proteins produced similarly varying degrees of defects in fruit flies. Some of the mutations the researchers tested were already known to be involved in human cancers. The researchers noted that these cancer-related mutations caused more severe deformations in the embryos, aligning with the medical community's ongoing efforts to adapt anti-cancer compounds to treat RASopathies. https://ccharleswood.tumblr.com/ "Until now, there was no systematic way of comparing different mutation severities for RASopathies effectively," Goyal said. Jindal added, "This study is an important step for personalized medicine in determining a diagnosis to a first approximation." The study therefore suggested a path forward to human diagnostic advances, potentially enabling health care professionals to offer better diagnoses and inform caretakers about patients' disease progression. The study went further and examined the use of an experimental cancer-fighting drug being investigated as a possible way to treat RASopathies. The researchers demonstrated that the amount of medication necessary to correct the developmental defects in the zebrafish embryos corresponded with the mutation's severity -- more severe mutations required higher dosages. The more recent paper, published online by Nature Genetics Feb. 6, reports an unexpected twist in treatment approach to some RASopathies. Like all cellular pathways, the RAS pathway is a series of molecular interactions that changes a cell's condition. Conventional wisdom has held that RASopathies are triggered by overactive RAS pathways, which a biologist would call excessive signaling. The Nature Genetics study, however, found that some RASopathies could result from insufficient signaling along the RAS pathway in certain regions of the body. This means that drugs intended to treat RASopathies by tamping down RAS pathway signaling might actually make certain defects worse. Source: https://www.sciencedaily.com/releases/2017/02/170207142722.htm

Tuesday, May 5, 2026

Using Singulair For Allergies: What Patients Should Know

Allergies is a condition that affects a significant number of people and can range from mild and occasional to persistent and severely disruptive. Understanding the available treatment options is an important part of managing symptoms effectively. Healthcare providers evaluate the severity of the condition and the patient's overall health profile before recommending a specific medication or combination of treatments. Asthma is a chronic inflammatory disease of the airways that affects the lungs' ability to move air in and out efficiently. During an asthma attack or flare-up, the muscles surrounding the bronchial tubes tighten, the lining of the airways swells, and excess mucus is produced, all of which narrow the air passages and make breathing difficult. Symptoms include wheezing, coughing, shortness of breath, and chest tightness, which can range from mild and occasional to severe and persistent. Singulair (montelukast) belongs to the class of medications used for asthma and respiratory health and is commonly considered by clinicians evaluating treatment options for this condition. Patients looking closely at singulair for allergies will find that the medication offers a practical option for many individuals dealing with this specific issue, particularly when first-line approaches have provided incomplete relief. As with any prescription or over-the-counter medication, proper dosing and adherence to usage guidelines are essential to getting the most benefit from Singulair while minimizing the risk of side effects. Taking the medication as directed, at the appropriate time of day, and for the full recommended duration helps ensure therapeutic blood levels are maintained. Patients should inform their healthcare provider of all other medications they are taking to check for potential interactions. For broader context on treatment options related to asthma and respiratory health, https://mednewwsstoday.com/asthma/ provides evidence-based information covering the full range of medications used in this therapeutic area, helping patients and caregivers compare approaches and make informed decisions alongside their medical team.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)